Preclinical Efficacy and Safety of VEGF-Grab, a Novel Anti-VEGF Drug, and Its Comparison to Aflibercept

Hong, Hye Kyoung; Park, Young Joo; Kim, Duk Ki; Ryoo, Na Kyung; Ko, Young Tae; Park, Kyu Hyung; Kim, Ho Min; Woo, Se Joon

doi:10.1167/iovs.61.13.22

Cited by 11 publications

(7 citation statements)

References 43 publications

(55 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although anti-VEGF drugs are targeted at the etiological treatment, there are di erences in individual responses to anti-VEGF therapy, and neovascularization usually requires repeated multiple injections [20][21][22][23]. Moreover, the high price of anti-VEGF drugs brings a serious economic burden to patients and the whole society, which is difficult for ordinary patients to bear [24]. In traditional Chinese medicine, neovascular eye disease belongs to the category of blurred vision.…”

Section: Discussionmentioning

confidence: 99%

Clinical Effect of Tongmai Fuming Decoction on Neovascular Ophthalmopathy

Yang

Zhou

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Background. The incidence of neovascular eye disease is increasing year by year, seriously threatening human vision health and becoming an urgent public health problem. Tongmai fuming decoction as an experienced prescription can treat ischemic eye disease. Objective. To investigate the therapeutic effect of Tongmai fuming decoction combined with anti-VEGF therapy on neovascular ophthalmopathy. Methods. 52 patients (62 eyes) with neovascular ophthalmopathy who met the inclusion criteria from January 2018 to July 2020 were randomly divided into the control and observation groups. The control group was given an intravitreal injection of antivascular endothelial growth factor (VEGF) drugs once a day combined with on-demand treatment. The observation group was treated with traditional Chinese medicine Tongmai fuming decoction in addition to the treatment of anti-VEGF drugs. The best-corrected visual acuity (BCVA) was examined before and after treatment, and optical coherence tomography angiography (OCTA) was used to examine the mean retinal thickness and neovascularization in the macular area. Patients were followed for one year and the number of anti-VEGF injections was recorded. Results. After treatment, the average thickness of BCVA and macular retina in the two groups significantly improved. The BCVA of the control group was 0.59 ± 0.39 3 months after treatment, and that of the experimental group was 0.42 ± 0.25 3 months after treatment. The average thickness of the macular retina in the control group was 304.8 ± 79.7 3 months after treatment, and that in the experimental group was 267.7 ± 64.6 3 months after treatment; The average number of injections of anti-VEGF therapy in the control group was 2.32 ± 1.15 times, and that in the experimental group was 1.74 ± 0.76 times. There was a significant difference between the two groups. Conclusion. Tongmai fuming decoction and anti-VEGF therapy have a synergistic effect in the treatment of neovascular ophthalmopathy, which can reduce the treatment times of anti-VEGF drugs.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical Effect of Tongmai Fuming Decoction on Neovascular Ophthalmopathy

Yang

Zhou

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…A single dose of aflibercept injection might be effective due to its higher affinity for VEGF in comparison with other anti-VEGFs. [ 10 ] It might be a treatment alternative that can be considered in CNVM due to uncommon etiologies.…”

Section: Discussionmentioning

confidence: 99%

Bietti crystalline dystrophy complicated by choroidal neovascularization treated with a single dose of aflibercept

Özbek

Pehlivanoğlu²,

Artunay³

2023

Oman Journal of Ophthalmology

View full text Add to dashboard Cite

Bietti crystalline dystrophy is a rare hereditary autosomal recessive disease that causes photoreceptor loss secondary to degeneration of retinal pigment epithelium due to intracellular retinal pigment epithelial crystalline deposits and abnormal lipid metabolism. We aimed to present a case of choroidal neovascular membrane secondary to Bietti crystalline dystrophy diagnosed with multimodal imaging and treated with an intravitreal injection of aflibercept. A single dose of aflibercept injection might be effective due to its higher affinity for vascular endothelial growth factor (VEGF) in comparison with other anti-VEGFs. It might be a treatment alternative that can be considered in the choroidal neovascular membrane due to uncommon etiologies.

show abstract

“…Aflibercept has received the approval of the US Food and Drug Administration (FDA) for the treatment of wet AMD and colorectal cancer. There exist many articles that have already investigated Aflibercept effects on tube formation and proliferation of endothelial cells 91‐93 . Researchers in the recent study investigated whether ERBB4 rejuvenates aged MSC and how ERBB4 enhances the therapeutic efficacy of aged MSC in treating myocardial infarction (MI).…”

Section: Discussionmentioning

confidence: 99%

Network analysis and the impact of Aflibercept on specific mediators of angiogenesis in HUVEC cells

Latifi-Navid

Soheili

Samiei

et al. 2021

J Cellular Molecular Medi

View full text Add to dashboard Cite

Angiogenesis, inflammation and endothelial cells’ migration and proliferation exert fundamental roles in different diseases. However, more studies are needed to identify key proteins and pathways involved in these processes. Aflibercept has received the approval of the US Food and Drug Administration (FDA) for the treatment of wet AMD and colorectal cancer. Moreover, the effect of Aflibercept on VEGFR2 downstream signalling pathways has not been investigated yet. Here, we integrated text mining data, protein‐protein interaction networks and multi‐experiment microarray data to specify candidate genes that are involved in VEGFA/VEGFR2 signalling pathways. Network analysis of candidate genes determined the importance of the nominated genes via different centrality parameters. Thereupon, several genes—with the highest centrality indexes—were recruited to investigate the impact of Aflibercept on their expression pattern in HUVEC cells. Real‐time PCR was performed, and relative expression of the specific genes revealed that Aflibercept modulated angiogenic process by VEGF/PI3KA/AKT/mTOR axis, invasion by MMP14/MMP9 axis and inflammation‐related angiogenesis by IL‐6‐STAT3 axis. Data showed Aflibercept simultaneously affected these processes and determined the nominated axes that had been affected by the drug. Furthermore, integrating the results of Aflibercept on expression of candidate genes with the current network analysis suggested that resistance against the Aflibercept effect is a plausible process in HUVEC cells.

show abstract

Preclinical Efficacy and Safety of VEGF-Grab, a Novel Anti-VEGF Drug, and Its Comparison to Aflibercept

Cited by 11 publications

References 43 publications

Clinical Effect of Tongmai Fuming Decoction on Neovascular Ophthalmopathy

Clinical Effect of Tongmai Fuming Decoction on Neovascular Ophthalmopathy

Bietti crystalline dystrophy complicated by choroidal neovascularization treated with a single dose of aflibercept

Network analysis and the impact of Aflibercept on specific mediators of angiogenesis in HUVEC cells

Contact Info

Product

Resources

About